Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192114 | 0.91 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL4185237 | 0.90 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL13875639 | 0.89 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL14220137 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL13890529 | 0.82 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL4187134 | 0.81 | KCNK3 (0.49) | MEN1KMT2AMAPTRXFP1NPC1 | |
| SCHEMBL1766542 | 0.79 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL13875641 | 0.79 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL4187726 | 0.79 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL1767299 | 0.77 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | MITSUI CHEMICALS, INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | MITSUI CHEMICALS, INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| EP-1916236-A1 | AMIDE DERIVATIVE, PESTICIDE CONTAINING SUCH COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | CYP2E1, GSTA1, CYP2S1 | MEN1 4524/4885KMT2A 499/4885SMN1; SMN2 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.